News round-up for 6-10 November by DDW Digital Content Editor Diana Spencer.
With the first DDW Turning Science into Business Summit taking place next week on the theme of Cancer Research, this dynamic area of drug discovery is my round-up focus again. Most significantly, this week has seen the UK approval of a new indication for anastrozole in the prevention of breast cancer and a number of significant findings in the field of immunotherapy announced at SITC 2023.
The top stories:
MHRA approves drug for lung cancer with limited therapy options
The UK regulator has approved a new treatment for non-small cell lung cancer (NSCLC) in adults that has a mutation and produces a rare protein called KRAS G12C.
UK-Dutch alliance to strengthen early clinical oncology research
Cancer Research UK and the KWF Dutch Cancer Society (KWF) have announced a new multi-project strategic partnership to advance promising therapeutic agents for cancer.
UK women to benefit from drug to prevent breast cancer
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has authorised a new indication for anastrozole, to prevent breast cancer in post-menopausal women at moderate or high risk of developing the disease.
DDW Cancer Research Summit: How to unlock genomic insights
The DDW Turning Science into Business Summit, ‘Cancer research opportunities and advances’ is a free summit offering expert thought leadership on cancer research, precision medicine and immunotherapy.
Latest advances in immunotherapy from SITC 2023
The Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting (SITC 2023) took place on 1-5 November 2023, at San Diego Convention Center in San Diego, US.
